Duloxetine Delayed-Release Capsules USP, 60mg, Rx Only, 90-count bottle, Mfr. by Towa Pharmaceutical Eurpoe S.L., Marto
Breckenridge Pharmaceutical, Inc.
CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
1 recall found for Breckenridge Pharmaceutical, Inc. — April 2026.
The recalls listed below are active notices associated with Breckenridge Pharmaceutical, Inc. in the FDA, NHTSA, USDA, and CPSC databases. None of the current recalls are classified as urgent. Check the specific lot numbers, model numbers, or production date codes in each notice carefully — a recall typically covers specific production runs, not everything a manufacturer sells.
A manufacturer appearing in the recall database does not indicate an ongoing safety failure. High-volume companies with large product lines naturally appear more frequently. What matters is whether your specific product — identified by lot number, model number, or date code — is included in a recall notice.
Browse all medication recalls →Breckenridge Pharmaceutical, Inc.
CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit